FDA Issues Investigational New Animal Drug (INAD) Number To Quigley Pharma Inc. To Study Its Anti-Inflammatory Compound QR-440 On Arthritis In Dogs
DOYLESTOWN, Pa., Jan. 31 /PRNewswire-FirstCall/ -- The Quigley Corporation today announced that its wholly-owned subsidiary Quigley Pharma has received an additional Investigational New Animal Drug (INAD) number from the Center for Veterinary Medicine of the Food and Drug Administration to study its naturally-derived, broad-spectrum anti-inflammatory compound QR-440 on dogs.
Canine arthritis afflicts an estimated 70 to 80 percent of dogs in certain breeds, particularly larger breeds. As in humans, canine arthritis becomes more symptomatic with age. Rheumatoid arthritis occurs most commonly in toy or small breeds, generally between 5 and 6 years of age.
Dr. Richard Rosenbloom, Quigley Pharma's Chief Operations Officer stated, "Further development and testing of this unique compound as a potential drug for veterinary use is both important for dogs and their owners, supporting our ongoing research process to develop this compound for human use."
In previous studies, QR-440 has been shown to reduce inflammation and also suggests possible disease-modifying potential. Rheumatoid arthritis affects about 1% of the U.S. population. It is three times more common in women than in men. It usually occurs in middle age, however, young children and the elderly can also develop it.
Guy Quigley, President and CEO of The Quigley Corporation stated, "Further development and testing of this unique compound as a veterinary drug could potentially result in it meeting the needs of a significant untapped market. It is the next step in finding a safe anti-inflammatory through the use of naturally-derived compounds."
The Quigley Corporation is the leading developer and marketer of diversified health products. The company's proven success in launching first-in-category health solutions supports the Pharma subsidiary in its efforts to develop strong pharmaceutical compounds targeting diverse conditions such as diabetes and rheumatoid arthritis with naturally derived compounds and botanicals.
The Quigley Corporation makes no representation that the U.S. Food and Drug Administration or any other regulatory agency will grant an IND or take any other action to allow the aforementioned compound to be studied or marketed. Furthermore, no claim is made that the potential medicine discussed here is safe, effective, or approved by the Food and Drug Administration.
About The Quigley Corporation
The Quigley Corporation is a leading developer and marketer of diversified health products including the COLD-EEZE(R) family of patented zinc gluconate glycine (ZIGG(tm)) lozenges and sugar free tablets. In October of 2004, The Company, through its wholly owned subsidiary, Quigley Manufacturing, Inc. acquired two FDA approved facilities to manufacture its COLD-EEZE(R) branded lozenges. InnerLight Inc., a wholly owned subsidiary, was formed in December 2000 for the purpose of introducing new products to the marketplace through a network of independent distributors. In addition to Over-The-Counter (OTC) products, the Company has formed Quigley Pharma Inc. (http://www.QuigleyPharma.com), a wholly owned ethical pharmaceutical subsidiary, to introduce a line of naturally derived patented prescription drugs. The Quigley Corporation's customers include leading national wholesalers and distributors, as well as independent and chain food, drug and mass merchandise stores and pharmacies.
Certain statements in this press release are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and involve known and unknown risk, uncertainties and other factors that may cause the company's actual performance or achievements to be materially different from the results, performance or achievements expressed or implied by the forward-looking statement. Factors that impact such forward-looking statements include, among others, changes in worldwide general economic conditions, changes in interest rates, government regulations, and worldwide competition.
CONTACT: Media Investor Relations Karen Pineman Carl Hymans G.S. Schwartz & Co. G.S. Schwartz & Co. 212.725.4500 212.725.4500 email@example.com@schwartz.comThe Quigley Corporation
CONTACT: Media: Karen Pineman, +1-212-725-4500, firstname.lastname@example.org; orInvestor Relations: Carl Hymans, +1-212-725-4500, email@example.com, bothof G.S. Schwartz & Co. for The Quigley Corporation
Web site: http://www.quigleyco.com/